Related Articles
00 / 00
-
-
Suraj Peri, PhD, assistant research professor at Fox Chase, and lead author of the study
-
-
Fox Chase Study Examines Protein Expression Biomarkers in HPV Negative Squamous-Cell
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First, is scheduled to end on July 31st. Learn about your options to continue receiving care at Temple Health.
Understanding the genetic alterations that lead to head and neck cancer is essential to fighting the disease. At Fox Chase, a multidisciplinary team of researchers and clinicians meets regularly to review translational research initiatives to identify and characterize new biomarkers of head and neck cancers that lead to new, innovative prevention and targeted therapy options for our patients.
Clinical and research fellows are welcome to attend this TRDG meeting. Also, any faculty who have an interest in participation please communicate with Alison Conn.
Support for our research initiatives allows Fox Chase to have a continued stake in the future of translational research, and the Center encourages our researchers and clinician to apply for grant funding to advance the mission to prevail over cancer. Below is a list of current research funding opportunities:
NCI Clinical and Translation Exploratory/Development Studies (R21)
As a nonprofit institution, support from our donors allows Fox Chase to remain one of the top cancer research and treatment centers in the county. Through donations, planned gifts, and membership to our giving societies, our supporters ensure Fox Chase remains at the forefront of head and neck cancer research and novel treatment options that save lives.
To give to the head and neck cancer research program, visit foxchase.org/giving
.
Suraj Peri, PhD, assistant research professor at Fox Chase, and lead author of the study
Fox Chase Study Examines Protein Expression Biomarkers in HPV Negative Squamous-Cell